Latest news with #moleculardiagnostics
Entrepreneur
20 hours ago
- Business
- Entrepreneur
Biopeak Raises USD 3.5 Million to Expand AI-Driven Health Clinics
"We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," says Rishi Pardal, Co-founder and CEO of Biopeak Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Biopeak, a wellness and longevity-focused startup headquartered in Bengaluru, has raised USD 3.5 million (approximately INR 29 crore) in seed funding from a group of notable investors. The round saw participation from Accel founding partner Prashanth Prakash, Claypond Capital--the family office of Manipal Group chairman Ranjan Pai and NKSquared, the investment arm of Zerodha co-founder Nikhil Kamath. Founded in 2024 by Rishi Pardal and Shiva Subramanian, Biopeak delivers personalised health services through its own clinics, combining advanced diagnostics, molecular science, and artificial intelligence (AI) to monitor early signs of physiological change. The company launched its first clinic in Bengaluru in March 2025. The funding will be used to expand Biopeak's clinic footprint across key Indian cities and strengthen its AI-based diagnostic and care delivery platform. "We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," said Rishi Pardal, Co-founder and CEO of Biopeak. "Our platform translates these insights into actionable, individualised health plans aimed at extending one's healthspan, not just lifespan." Biopeak's approach includes a suite of diagnostic tools such as microbiome mapping, organic acid profiling, salivary cortisol rhythm analysis, and whole-exome functional genomics. These are integrated with non-invasive imaging technologies including MRI, CT, DXA, and ECHO, along with tissue-level screenings to assess toxin levels, mineral balance, and oxidative stress. Clients typically undergo more than six hours of detailed consultations guided by a dedicated health manager and a multidisciplinary team of specialists. Health plans are updated regularly based on follow-up tests and consultations. Commenting on the investment, Prashanth Prakash said, "As India's population ages, our challenge is to build systems that not only extend life but also improve the quality of those extended years. Geroscience, early interventions, and scalable healthcare models will be central to this shift." Prakash, who also mentors Biopeak, is the Founding Patron of Longevity India, a platform focused on ageing research and interventions tailored for India's demographic needs.
Yahoo
20-05-2025
- Health
- Yahoo
North America Infectious Disease Rapid Diagnostics Market Report 2025-2035 Featuring Abbott, F. Hoffmann-La Roche, Danaher, DiaSorin, Hologic, BGI, Quidel, Cellex, bioMerieux, Thermo Fisher Scientific
The North American infectious disease rapid diagnostics market is growing due to rising incidences of diseases like influenza and STIs, driving demand for fast diagnostic tests. Key technologies include molecular diagnostics and antigen tests, crucial for early detection and managing infections. The U.S. leads the market, benefiting from a robust healthcare system and regulatory support. Challenges include strict FDA regulations and high costs. Major players like Abbott and Thermo Fisher are innovating to meet rising demands for effective, rapid diagnostics. Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "North America Infectious Disease Rapid Diagnostics Market - A Regional Analysis: Focus on Product, Technology, Application, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to Disease Rapid Diagnostics are tests designed to quickly detect and identify infectious agents such as bacteria, viruses, or fungi, enabling fast treatment decisions. These tests provide results in minutes to a few hours, crucial for early detection and effective management of infections. They include molecular diagnostics, antigen tests, and serological assays for diseases such as influenza, COVID-19, and increasing incidence of infectious diseases such as influenza, sexually transmitted infections (STIs), respiratory infections, and hospital-acquired infections (HAIs) is a major driver of the North American rapid diagnostics market. For instance, the CDC reported in 2023 that the U.S. experienced an uptick in flu cases, with over 15 million cases reported that year, emphasizing the need for fast and efficient diagnostic tests. The growing threat of antimicrobial resistance (AMR) and the emergence of novel pathogens, such as the resurgence of multidrug-resistant tuberculosis and the rise of drug-resistant gonorrhea, have made early and accurate disease detection more critical than ever to control outbreaks and prevent further governments and healthcare organizations are heavily investing in rapid testing solutions to enhance early disease detection and control outbreaks. During the 2023 influenza season, the U.S. government expanded the use of Quidel's Sofia 2 SARS Antigen FIA test for quick identification of flu and COVID-19 co-infections in emergency departments. The demand for point-of-care (POC) diagnostics in emergency settings, outpatient clinics, and remote locations has risen as healthcare systems strive to reduce diagnostic turnaround times and improve patient outcomes. For instance, the Abbott ID NOW molecular diagnostic system has been deployed widely in rural and remote areas to quickly detect respiratory infections such as flu and COVID-19, providing results in just 15 minutes.A significant opportunity in the North American rapid diagnostics market lies in the expansion of point-of-care testing (POCT) across decentralized healthcare settings, such as pharmacies, urgent care centers, and home-based testing. The rising demand for fast, reliable, and affordable diagnostics outside of traditional hospital environments is opening new growth avenues for diagnostic companies. With growing government support and increasing regulatory approvals for POCT, the adoption of portable diagnostic devices is expected to surge, particularly for diseases like STIs, respiratory infections, and gastrointestinal the major challenges faced by the North America infectious disease rapid diagnostics market are the stringent regulatory framework and pricing constraints. The FDA approval process for new diagnostic tests can be time-consuming and complex, delaying product launches and market entry. For instance, Cepheid's Xpert Xpress COVID-19 test, while highly effective, faced regulatory hurdles and delays before it received Emergency Use Authorization (EUA) in 2020. The approval process for new technologies can extend product launch timelines, delaying access to critical the high cost of advanced molecular diagnostic technologies such as q-PCR and INAAT makes them less accessible, particularly in resource-limited settings. Although reimbursement policies are improving, inconsistent insurance coverage for rapid diagnostic tests remains a barrier to widespread adoption. A study published by the National Institutes of Health (NIH) found that the cost of a single qPCR test for COVID-19 could range from $100 to $200, limiting accessibility in smaller clinics or remote healthcare pressures also arise due to competition from generic or low-cost diagnostic alternatives, especially in non-hospital settings. Moreover, healthcare providers are often hesitant to adopt new diagnostic technologies without clear cost-effectiveness data or strong clinical validation. These regulatory and pricing challenges could slow market growth and limit accessibility to cutting-edge diagnostic market players in the North American infectious disease rapid diagnostics market are focusing on innovation, strategic partnerships, and expanding product offerings to meet the growing demand for faster, more accurate testing solutions. For instance, in April 2022, Thermo Fisher Scientific, Inc. launched the TaqPath COVID-19 RNase P 2.0 Assay Kit, designed to detect SARS-CoV-2, including emerging players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, DiaSorin S.p.A, Hologic, Inc., BGI Group,Quidel Corporation, Cellex,bioMerieux S.A., and Thermo Fisher Scientific Inc., etc. Assay to Lead the Infectious Disease Rapid Diagnostics MarketAssays dominate the North America infectious disease rapid diagnostics market due to their widespread applicability, affordability, and efficiency in detecting a range of infectious diseases. Assays, including immunoassays and molecular assays, are used extensively in hospitals, clinics, and point-of-care (POC) settings for rapid disease detection, enabling timely treatment decisions. Their cost-effectiveness compared to fully automated diagnostic systems makes them accessible to a broader range of healthcare the rising prevalence of infectious diseases such as respiratory infections, sexually transmitted infections (STIs), and gastrointestinal infections, demand for rapid and accurate diagnostic assays is increasing. Advances in multiplex assays, capable of detecting multiple pathogens from a single sample, further enhance their clinical value. Additionally, regulatory approvals for at-home diagnostic assays, particularly for diseases like COVID-19 and influenza, are expected to drive market expansion. As a result, assays remain a cornerstone of infectious disease diagnostics. Real-Time Polymerase Chain Reaction (q-PCR) to Lead the Infectious Disease Rapid Diagnostics MarketReal-Time Polymerase Chain Reaction (q-PCR) is projected to be the dominant technology in the North America infectious disease rapid diagnostics market due to its high sensitivity, specificity, and rapid turnaround time. q-PCR is widely used for detecting viral and bacterial infections, particularly in hospital laboratories and reference labs where accuracy is crucial for clinical key advantage of q-PCR is its ability to quantify pathogen load, enabling physicians to monitor disease progression and treatment effectiveness. The increasing incidence of respiratory infections (e.g., COVID-19, influenza, RSV) has led to widespread adoption of q-PCR tests. Moreover, innovations in portable and automated q-PCR devices are expanding the technology's usability in point-of-care (POC) and decentralized ongoing advancements in multiplex PCR assays, which allow simultaneous detection of multiple pathogens, q-PCR will continue to be the gold standard for rapid, high-accuracy infectious disease diagnostics.U.S. Region to Lead the North America Infectious Disease Rapid Diagnostics Market (by Country)The U.S. is expected to lead the North America infectious disease rapid diagnostics market throughout the forecast period due to several key factors. The country has a high prevalence of infectious diseases, such as respiratory, gastrointestinal, and sexually transmitted infections, which drives the demand for rapid diagnostic solutions. The U.S. also boasts a robust healthcare infrastructure with well-established hospitals, diagnostic centers, and research institutions that promote the adoption of innovative diagnostic technologies. Regulatory support from the FDA, including expedited approval pathways, allows faster market entry for new diagnostic products, further fueling growth. Additionally, increased investments from government initiatives, private sector funding, and collaborations between biotech companies and academic institutions are boosting R&D in rapid diagnostics. The U.S. remains at the forefront of adopting advanced diagnostic technologies, including molecular diagnostic platforms, AI-driven tools, and portable rapid test kits. While Canada experiences steady growth, the U.S. will continue to be the primary driver of market expansion in the region. Key Topics Covered:1. Markets: Industry Outlook1.1 Trends: Current and Future Impact Assessment1.2 R&D Review1.2.1 Patent Filing Trend by Year1.3 Regulatory Landscape1.4 Market Dynamics1.4.1 Market Drivers1.4.2 Market Restraints1.4.3 Market Opportunities2. North America Infectious Disease Rapid Diagnostic Market (by Product)2.1 Assays2.2 Platforms3. North America Infectious Disease Rapid Diagnostic Market (by Technology)3.1 Real-Time PCR (q-PCR)3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)3.3 Others4. North America Infectious Disease Rapid Diagnostic Market (by Application)4.1 Respiratory Infection4.2 Gastro-Intestinal Infection4.3 Hospital Acquired Infection4.4 Sexually Transmitted Infections4.5 Others5. North America Infectious Disease Rapid Diagnostic Market (by Country)5.1 U.S5.2 Canada6. Competitive Landscape and Company Profiles 6.1 Key Strategies and Developments6.1.1 Product Approvals6.1.2 Product Launches and Upgradations6.1.3 Synergistic Activities6.1.4 Funding and Expansion6.1.5 Mergers and Acquisitions6.2 Company Profiles6.2.1 Company Overview6.2.2 Product Portfolio6.2.3 Top Competitors6.2.4 Analyst View Abbott Laboratories F. Hoffmann-La Roche Ltd Danaher Corporation DiaSorin S.p.A Hologic, Inc. BGI Group Quidel Corporation Cellex bioMerieux S.A. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
14-05-2025
- Business
- Yahoo
South East Asia Molecular Diagnostics Market Forecast to 2031: PCR Technology Leads Growth, Kits & Reagents Hold Largest Share
The Southeast Asia molecular diagnostics market is set to grow from USD 528.3 million in 2024 to USD 891.9 million by 2031, at a 7.8% CAGR. Key drivers include a rising elderly population, increased disease prevalence, and advances in diagnostics technology. The market is segmented by offering, test type, technology, and application, with the infectious diseases segment holding the largest share. Geographically, Singapore leads, followed by Indonesia and Vietnam. Major players include Illumina, Thermo Fisher, and Roche. Challenges include regulatory harmonization and skilled professional shortages. Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "South East Asia Molecular Diagnostics Market by Offering (Reagents, Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, ISH, INAAT, Sequencing, Microarray), Application (HIV, Influenza, HPV, Oncology, Gene Testing), End User - Forecast to 2031" has been added to offering. The Southeast Asia molecular diagnostics market is anticipated to expand significantly, reaching USD 891.9 million by 2031 from USD 528.3 million in 2024, representing a compound annual growth rate (CAGR) of 7.8% within the forecast period. This growth trajectory is driven by factors such as an aging population, the rising prevalence of communicable and non-communicable diseases, and technological advancements in molecular diagnostics. Furthermore, increased healthcare spending across the region bolsters this market growth. The market faces challenges due to the lack of uniform medical device regulations across Southeast Asian countries and the high costs associated with molecular diagnostic tests. However, opportunities arise from the burgeoning medical tourism industry in Southeast Asia and an increasing focus on companion diagnostics. These avenues are expected to present substantial growth potential for key market players. Nevertheless, a key challenge remains in the shortage of skilled professionals in the field. Leading companies in the Southeast Asia molecular diagnostics market include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, among others. These companies are noted for their diverse product offerings and strategic developments aimed at enhancing their market presence between 2021 and 2024. The market is segmented based on offerings, test types, technology, application, and geography. In terms of offerings, kits and reagents accounted for the largest market share in 2024, driven by the availability of a wide range of diagnostic reagents and consumables. For test types, laboratory tests lead the market due to their high accuracy and cost-effectiveness compared to point-of-care tests. Technology-wise, the Polymerase Chain Reaction (PCR) segment holds the largest market share, attributed to its versatility and application in diagnostics. This growth was further accelerated during the COVID-19 pandemic due to increased testing capabilities in countries like Indonesia. Application-wise, infectious diseases account for the most significant market share. The need for rapid, sensitive and specific testing methods to control communicable diseases drive demand in this segment. The timely diagnosis through molecular diagnostics is crucial for managing these diseases effectively. Geographically, Singapore is projected to command the largest market share by 2024, followed by Indonesia and Vietnam. This is attributed to Singapore's advanced healthcare infrastructure, while Indonesia's market growth is driven by improvements in healthcare facilities and spending. Key questions addressed in the report include identifying high-growth market segments, exploring historical and forecasted market sizes, and understanding major drivers, restraints, and opportunities in the market. Furthermore, the report discusses the competitive landscape, recent developments, and strategic moves by major and emerging players in the Southeast Asia molecular diagnostics market. Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Insights5. Southeast Asia Molecular Diagnostics Market Assessment-by Offering6. Southeast Asia Molecular Diagnostics Market Assessment-by Test Type7. Southeast Asia Molecular Diagnostics Market Assessment-by Technology8. Southeast Asia Molecular Diagnostics Market, by Application9. Southeast Asia Molecular Diagnostics Market Assessment-by End User10. Southeast Asia Molecular Diagnostics Market Assessment-by Country11. Competitive Landscape12. Company Profiles Illumina Inc. (U.S.) Thermo Fisher Scientific Inc. (U.S.) F. Hoffmann-La Roche Ltd (Switzerland) Hologic Inc. (U.S.) Sansure Biotech Inc. (China) Agilent Technologies Inc. (U.S.) Danaher Corporation (U.S.) Abbott Laboratories (U.S.) Qiagen N.V. (Netherlands) Xiamen Zeesan Biotech Co. Ltd. (China). For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
